Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
26
GERN Quote, Financials, Valuation and Earnings
Last price:
$1.59
Seasonality move
:
7.37%
Day range:
$1.45 - $1.62
52-week range:
$1.45 - $5.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.42x
P/B ratio:
3.36x
Volume:
31.2M
Avg. volume:
18.5M
1-year change:
-53.31%
Market cap:
$942.6M
Revenue:
$77M
EPS (TTM):
-$0.27
Analysts' Opinion
-
Consensus RatingGeron has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.50, Geron has an estimated upside of 204.05% from its current price of $1.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.48.
Fair Value
-
According to the consensus of 6 analysts, Geron has 204.05% upside to fair value with a price target of $4.50 per share.
GERN vs. S&P 500
-
Over the past 5 trading days, Geron has underperformed the S&P 500 by -12.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Geron does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Geron has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Geron reported revenues of $47.5M.
Earnings Growth
-
Geron has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Geron reported earnings per share of -$0.04.
Enterprise value:
654.5M
EV / Invested capital:
--
Price / LTM sales:
12.42x
EV / EBIT:
--
EV / Revenue:
8.50x
PEG ratio (5yr expected):
-3.96x
EV / Free cash flow:
-2.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-36.92%
Net Income Margin (TTM):
-226.74%
Return On Equity:
-59.29%
Return On Invested Capital:
-45.4%
Operating Margin:
-42.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $596K | $237K | $77M | $23K | $47.5M | |
| Gross Profit | -- | -- | -- | $23K | $46.8M | |
| Operating Income | -$138.6M | -$193.9M | -$173.7M | -$54.3M | -$20.1M | |
| EBITDA | -$134.2M | -$174.8M | -$154.8M | -$49.4M | -$16.3M | |
| Diluted EPS | -$0.36 | -$0.33 | -$0.27 | -$0.09 | -$0.04 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $199.9M | $187.2M | $180.2M | $341.3M | $491M | |
| Total Assets | $270.7M | $226M | $190.6M | $394.1M | $593.8M | |
| Current Liabilities | $30.9M | $45.5M | $76.7M | $108.1M | $88.3M | |
| Total Liabilities | $59.8M | $99.6M | $110.6M | $146.1M | $313.5M | |
| Total Equity | $210.9M | $126.4M | $80M | $247.9M | $280.3M | |
| Total Debt | $24M | $49.8M | $51.2M | $81.9M | $118.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$127.4M | -$167.7M | -$218.6M | -$40.9M | -$43.9M | |
| Cash From Investing | $62.1M | -$180.3M | -$106M | $47.6M | -$103.5M | |
| Cash From Financing | $87.3M | $362M | $334.4M | $33.3M | $166.2M | |
| Free Cash Flow | -$127.8M | -$168.6M | -$219.3M | -$41M | -$43.8M | |
GERN
Sector
Market Cap
$942.6M
$35.9M
Price % of 52-Week High
27.72%
42.55%
Dividend Yield
0%
0%
Shareholder Yield
-7.18%
-1.03%
1-Year Price Total Return
-53.31%
-44.4%
Beta (5-Year)
0.661
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.67
200-day SMA
Sell
Level
$3.76
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.69
Relative Strength Index (RSI14)
Sell
Level
36.39
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-93.1818
50-day SMA
Sell
Level
$2.28
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0062)
Sell
CA Score
(Annual)
Level (-1.6694)
Sell
Beneish M-Score
(Annual)
Level (285.8367)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.968)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Stock Forecast FAQ
In the current month, GERN has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The GERN average analyst price target in the past 3 months is $4.50.
-
Where Will Geron Stock Be In 1 Year?
According to analysts, the consensus estimate is that Geron share price will rise to $4.50 per share over the next 12 months.
-
What Do Analysts Say About Geron?
Analysts are divided on their view about Geron share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Geron is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Geron's Price Target?
The price target for Geron over the next 1-year time period is forecast to be $4.50 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is GERN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Geron is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GERN?
You can purchase shares of Geron via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Geron shares.
-
What Is The Geron Share Price Today?
Geron was last trading at $1.59 per share. This represents the most recent stock quote for Geron. Yesterday, Geron closed at $1.48 per share.
-
How To Buy Geron Stock Online?
In order to purchase Geron stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
